ScreenerHero

ACHV Achieve Life Sciences, Inc.

NAS · US · Healthcare · Biotechnology · achievelifesciences.com
7.240USD+2.99%Mkt Cap: 746.46M $P/E: —

Achieve Life Sciences, Inc., a late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom. The company offers cytisinicline…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap746.46M USD
Enterprise Value551.05M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-54.65M USD
Revenue/Share—
Last Price7.240 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees28
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-10.77
PEG17.68
EV/EBITDA-9.49
EV/Revenue—
P/S—
P/B-49.16
EPS (TTM)-1.70
EPS (Forward)-0.65
52W Range
2.62077% of range8.610
52W High8.610 USD
52W Low2.620 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-253.96%
ROA-130.77%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-49.47M USD
CapEx (TTM)4.00K USD
FCF Margin—
FCF Yield20.94%
Net Debt-172.36M USD
Net Debt/EBITDA2.97
Balance Sheet
Debt/Equity0.69
Current Ratio0.95
Quick Ratio0.95
Book Value/Sh-0.14 USD
Cash/Share1.82 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay DateJul 31, 2020
Splits
Last Split1:20
Split DateJul 31, 2020
Analyst Consensus
Rating1.3 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)14.15 USD
Upside (mean)+95.5%
Target Range9.000 USD – 21.00 USD
9.000+95.5% to mean21.00
# Analysts13
Ownership
Shares Out.103.10M
Float74.69M
Insiders0.91%
Institutions82.06%
Short Interest
Short Ratio10.2d
Short % Float15.63%
Short % Out.15.54%
Shares Short15.99M
Short (prev mo.)16.42M
Technical
SMA 507.474 (-3.1%)
SMA 2005.468 (+32.4%)
Beta2.31
S&P 52W Chg16.45%
Avg Vol (30d)1.63M
Avg Vol (10d)1.44M
Technical Indicators
RSI (14)45.6
MACD-0.0595
MACD Signal0.0524
MACD Hist.-0.1119
BB Upper8.296 USD
BB Middle7.560 USD
BB Lower6.824 USD
BB Width19.47%
ATR (14)0.4460 USD
Vol Ratio (20d)0.61x